Table of Contents
Thrombosis
Volume 2012 (2012), Article ID 758385, 9 pages
http://dx.doi.org/10.1155/2012/758385
Review Article

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?

1Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, M365 Starling Loving Hall, 410 W 10th Avenue, Columbus, OH 43210, USA
2Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, A454 Starling Loving Hall, 410 W 10th Avenue, Columbus, OH 43210, USA

Received 29 June 2012; Accepted 10 August 2012

Academic Editor: Lars Carl Borris

Copyright © 2012 Ludmila Katherine Martin and Tanios Bekaii-Saab. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Cushman, A. W. Tsai, R. H. White et al., “Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology,” American Journal of Medicine, vol. 117, no. 1, pp. 19–25, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Heit, W. Michael O'Fallon, T. M. Petterson et al., “Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study,” Archives of Internal Medicine, vol. 162, no. 11, pp. 1245–1248, 2002. View at Google Scholar · View at Scopus
  3. I. A. Naess, S. C. Christiansen, P. Romundstad, S. C. Cannegieter, F. R. Rosendaal, and J. Hammerstrøm, “Incidence and mortality of venous thrombosis: a population-based study,” Journal of Thrombosis and Haemostasis, vol. 5, no. 4, pp. 692–699, 2007. View at Google Scholar
  4. A. Y. Lee and M. N. Levine, “Venous thromboembolism and cancer: risks and outcomes,” Circulation, vol. 107, pp. I17–I21, 2003. View at Google Scholar
  5. H. T. Sørensen, L. Mellemkjaer, J. H. Olsen, and J. A. Baron, “Prognosis of cancers associated with venous thromboembolism,” The New England Journal of Medicine, vol. 343, no. 25, pp. 1846–1850, 2000. View at Google Scholar
  6. H. K. Chew, T. Wun, D. Harvey, H. Zhou, and R. H. White, “Incidence of venous thromboembolism and its effect on survival among patients with common cancers,” Archives of Internal Medicine, vol. 166, no. 4, pp. 458–464, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Shah, M. Capanu, G. Soff, T. Asmis, and D. P. Kelsen, “Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies,” Journal of Thrombosis and Haemostasis, vol. 8, no. 8, pp. 1702–1709, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Khorana, N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis, “Development and validation of a predictive model for chemotherapy- associated thrombosis,” Blood, vol. 111, no. 10, pp. 4902–4907, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Wun and R. H. White, “Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors,” Cancer Investigation, vol. 27, no. 1, pp. 63–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. S. Epstein, G. A. Soff, M. Capanu et al., “Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer,” Cancer, vol. 118, no. 12, pp. 3053–3061, 2012. View at Google Scholar
  11. B. A. Hutten, M. H. Prins, M. Gent, J. Ginsberg, J. G. P. Tijssen, and H. R. Buller, “Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: a retrospective analysis,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3078–3083, 2000. View at Google Scholar · View at Scopus
  12. H. K. Jeon, D. U. Kim, D. H. Baek et al., “Venous thromboembolism in patients with cholangiocarcinoma: focus on risk factors and impact on survival,” European Journal of Gastroenterology & Hepatology, vol. 24, pp. 444–449, 2012. View at Google Scholar
  13. G. C. Connolly, R. Chen, O. Hyrien et al., “Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma,” Thrombosis Research, vol. 122, no. 3, pp. 299–306, 2008. View at Publisher · View at Google Scholar
  14. S. Sallah, J. Y. Wan, and N. P. Nguyen, “Venous thrombosis in patients with solid tumors: determination of frequency and characteristics,” Thrombosis and Haemostasis, vol. 87, no. 4, pp. 575–579, 2002. View at Google Scholar · View at Scopus
  15. L. A. Menapace, D. R. Peterson, A. Berry, T. Sousou, and A. A. Khorana, “Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer,” Thrombosis and Haemostasis, vol. 106, no. 2, pp. 371–378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Mandalà and C. Tondini, “The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer,” Expert Review of Anticancer Therapy, vol. 11, no. 4, pp. 579–588, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Mikal and A. J. A. Campbell, “Carcinoma of the pancreas. Diagnostic and operative criteria based on one hundred consecutive autopsies,” Surgery, vol. 28, no. 6, pp. 963–969, 1950. View at Google Scholar · View at Scopus
  18. J. R. Miller, A. H. Baggenstross, and M. W. Comfort, “Carcinoma of the pancreas; effect of histological types and grade of malignancy on its behavior,” Cancer, vol. 4, no. 2, pp. 233–241, 1951. View at Google Scholar · View at Scopus
  19. G. H. Sack Jr., J. Levin, and W. R. Bell, “Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features,” Medicine, vol. 56, no. 1, pp. 1–37, 1977. View at Google Scholar · View at Scopus
  20. J. Sgouros and A. Maraveyas, “Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer,” Acta Oncologica, vol. 47, no. 3, pp. 337–346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. P. A. Thodiyil and A. K. Kakkar, “Variation in relative risk of venous thromboembolism in different cancers,” Thrombosis and Haemostasis, vol. 87, no. 6, pp. 1076–1077, 2002. View at Google Scholar · View at Scopus
  22. M. J. Moore, D. Goldstein, J. Hamm et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1960–1966, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Prestidge, S. Lee, P. Harper, L. Young, and P. Ockelford, “Survival in patients with malignancy and venous thromboembolism by tumour subtype and thrombus location,” Journal of Internal Medicine, vol. 42, no. 1, pp. 71–74, 2012. View at Google Scholar
  24. R. A. Moore, N. Adel, E. Riedel et al., “High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis,” Journal of Clinical Oncology, vol. 29, no. 25, pp. 3466–3473, 2011. View at Google Scholar
  25. P. Prandoni, A. W. A. Lensing, A. Piccioli et al., “Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis,” Blood, vol. 100, no. 10, pp. 3484–3488, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Alcalay, T. Wun, V. Khatri et al., “Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival,” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1112–1118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. J. D. Douketis, M. A. Crowther, G. A. Foster, and J. S. Ginsberg, “Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?” The American Journal of Medicine, vol. 110, no. 7, pp. 515–519, 2001. View at Google Scholar · View at Scopus
  28. A. Y. Lee, M. N. Levine, R. I. Baker et al., “Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer,” The New England Journal of Medicine, vol. 349, no. 2, pp. 146–153, 2003. View at Google Scholar
  29. G. Meyer, Z. Marjanovic, J. Valcke et al., “Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study,” Archives of Internal Medicine, vol. 162, no. 15, pp. 1729–1735, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity,” Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. G. J. Hankey and J. W. Eikelboom, “Dabigatran etexilate: a new oral thrombin inhibitor,” Circulation, vol. 123, no. 13, pp. 1436–1450, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Tran and A. Cheng-Lai, “Dabigatran etexilate: the first oral anticoagulant available in the united states since warfarin,” Cardiology in Review, vol. 19, no. 3, pp. 154–161, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Stangier and A. Clemens, “Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor,” Clinical and Applied Thrombosis/Hemostasis, vol. 151, supplement, pp. 9S–16S, 2009. View at Google Scholar
  34. J. Stangier, K. Rathgen, H. Sthle, and D. Mazur, “Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study,” Clinical Pharmacokinetics, vol. 49, no. 4, pp. 259–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Schulman, C. Kearon, A. K. Kakkar et al., “Dabigatran versus warfarin in the treatment of acute venous thromboembolism,” The New England Journal of Medicine, vol. 361, pp. 2342–2352, 2009. View at Publisher · View at Google Scholar
  36. S. Schulman, D. Baanstra, H. Eriksson et al., “Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism,” Journal of Thrombosis and Haemostasis, vol. 9, article S22, 2011. View at Google Scholar
  37. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing, “Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor,” Clinical Pharmacology and Therapeutics, vol. 78, no. 4, pp. 412–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Kubitz, M. Becka, A. Roth, and W. Mueck, “Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects,” Current Medical Research and Opinion, vol. 24, no. 10, pp. 2757–2765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Bauersachs, S. D. Berkowitz, B. Brenner et al., “Oral rivaroxaban for symptomatic venous thromboembolism,” The New England Journal of Medicine, vol. 363, no. 26, pp. 2499–510, 2010. View at Google Scholar
  40. N. Raghavan, C. E. Frost, Z. Yu et al., “Apixaban metabolism and pharmacokinetics after oral administration to humans,” Drug Metabolism and Disposition, vol. 37, no. 1, pp. 74–81, 2009. View at Google Scholar
  41. R. Kreutz, “Pharmacodynamic and pharmacokinetic basics of rivaroxaban,” Fundamental & Clinical Pharmacology, vol. 26, no. 1, pp. 27–32, 2012. View at Google Scholar